Meiera P, Timmis A

Idioma: Español
Referencias bibliográficas: 119
Paginas: 133-149
Archivo PDF: 470.54 Kb.

RESUMEN

El campo de la cardiología intervencionista sigue avanzando rápidamente. La eficacia de las intervenciones percutáneas con las nuevas generaciones de stents liberadores de fármacos ha avanzado mucho en la última década. Esta mejora en el rendimiento del stent ha ampliado el nivel de indicación hacia intervenciones más complejas tales como intervencionismo del tronco coronario izquierdo y de múltiples vasos. En el campo del tratamiento médico coadyuvante continúan los grandes avances, como lo es el tratamiento antiplaquetario (bivalirudina, prasugrel, ticagrelor) que mejorará aún más los resultados del intervencionismo coronario percutáneo. Lo mismo ocurre para la imagenología intravascular como es el caso del ultrasonido intravascular y la tomografía de coherencia óptica. Sin embargo, la cardiología intervencionista se ha convertido en un campo bastante amplio, que incluye también la ablación septal con alcohol para la miocardiopatía hipertrófica obstructiva, etc. En la actualidad, las intervenciones estructurales constituyen el área de mayor crecimiento, sobre todo para la estenosis válvular aórtica (implantación de válvula aórtica transcatéter) y la regurgitación mitral (clipping mitral). En esta revisión se tratan los avances recientes en todos estos diferentes campos de la cardiología intervencionista.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Gray HH, Henderson RA, de Belder MA, et al. Guideline Development Group. Early management of unstable angina and non-ST-segment elevation myocardial infarction: summary of NICE guidance. Heart 2010;96:1662-8.

2. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-16.

3. Weintraub WS, Spertus JA, Kolm P, et al; COUR-AGE Trial Research Group, Mancini GB. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med 2008;359:677-87.

4. Stergiopoulos K, Brown DL. Initial coronary stent implantation with medical therapy vs medical therapy alone for stable coronary artery disease: meta-analysis of randomized controlled trials. Arch Intern Med 2012;172:312-19.

5. Henderson RA, O'Flynn N. Management of stable angina: summary of NICE guidance. Heart 2012; 98:500-7.

6. Borden WB, Redberg RF, Mushlin AI, et al. Patterns and intensity of medical therapy in pa-tients undergoing percutaneous coronary inter-vention. JAMA 2011;305:1882-9.

7. Aversano T, Lemmon CC, Liu L; Atlantic CPORT Investigators. Outcomes of PCI at hospitals with or without on-site cardiac surgery. N Engl J Med 2012;366:1792-802. Epub 2012 Mar 25.

8. Singh M, Holmes DR Jr, Dehmer GJ, et al. Percu-taneous coronary intervention at centers with and without on-site surgery: a meta-analysis. JAMA 2011;306:2487-94.

9. Epstein AJ, Polsky D, Yang F, et al. Coronary revas-cularization trends in the United States, 2001-2008. JAMA 2011;305:1769-76.

10. Taggart DP, Boyle R, de Belder MA, et al. The 2010 ESC/EACTS guidelines on myocardial revasculari-sation. Heart 2011;97:445-6.

11. Chan PS, Patel MR, Klein LW, et al. Appropriate-ness of percutaneous coronary intervention. JAMA 2011;306:53-61.

12. Cohen DJ, Van Hout B, Serruys PW, et al. Synergy between PCI with Taxus and Cardiac Surgery Investigators. Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery. N Engl J Med. 2011; 364:1016-26.

13. Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative effectiveness of revascularization strategies. N Engl J Med 2012;366:1467-76.

14. Rao SV, Kaltenbach LA, Weintraub WS, et al. Pre-valence and outcomes of same-day discharge after elective percutaneous coronary intervention among older patients. JAMA 2011;306:1461-7.

15. Khawaja FJ, Shah ND, Lennon RJ, et al. Factors associated with 30-day readmission rates after percutaneous coronary intervention. Arch Intern Med 2012;172:112-17.

16. Brennan JM, Dai D, Patel MR, et al. Characteristics and long-term outcomes of percutaneous revas-cularization of unprotected left main coronary artery stenosis in the United States: a report from the National Cardiovascular Data Registry, 2004 to 2008. J Am Coll Cardiol 2012;59:648-54.

17. Park SJ, Kim YH, Park DW, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Engl J Med 2011;364: 1718-27.

18. de la Torre Hernandez JM, Hernandez Hernandez F, Alfonso F, et al. LITRO Study Group (Spanish Working Group on Interventional Cardiology). Prospective application of pre-defined intravascular ultrasound criteria for assessment of inter-mediate left main coronary artery lesions results from the multicenter LITRO study. J Am Coll Cardiol 2011;58:351-8.

19. Garg S, Serruys PW. Drug-eluting stents: a re-appraisal. Heart 2010;96:489-93.

20. de Waha A, Dibra A, Kufner S, et al. Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with diabetes mellitus: a patient-level meta-analysis of randomized trials. Clin Res Cardiol 2011;100:561- 70.

21. Baber U, Mehran R, Sharma SK, et al. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol 2011;58:1569-77.

22. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012;379:1393-402.

23. Meier P, Brilakis ES, Corti R, et al. Drug-eluting versus bare-metal stent for treatment of saphenous vein grafts: a meta-analysis. PLoS One 2010;5:e11040.

24. Kalesan B, Pilgrim T, Heinimann K, et al. Com-parison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myo-cardial infarction. Eur Heart J 2012;33:977-87.

25. Serruys PW, Onuma Y, Dudek D, et al. Evaluation of the second generation of a bioresorbable ever-olimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011;58:1578-88.

26. Johnman C, Pell JP, Mackay DF, et al. Clinical out-comes following radial versus femoral artery access in primary or rescue percutaneous co-ronary intervention in Scotland: retrospective co-hort study of 4534 patients. Heart 2012;98:552-7.

27. Patterson T, Foale RA. If the radial artery is the new standard of care in primary percutaneous coronary intervention, why is most intervention done by the femoral approach? Heart 2011;97: 521-2.

28. Cayla G, Silvain J, Barthelemy O, et al. Trans-radial approach for catheterisation in non-ST segment

29. elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study. Heart 2011;97:887-91.

30. Mamas MA, Ratib K, Routledge H, et al. Influence of access site selection on PCI- related adverse events in patients with STEMI: meta-analysis of randomised controlled trials. Heart 2012;98:303-11.

31. Vink MA, Amoroso G, Dirksen MT, et al. Routine use of the transradial approach in primary percutaneous coronary intervention: procedural aspects and outcomes in 2209 patients treated in a single high-volume centre. Heart 2011;97:1938-42.

32. Amoroso G, Kiemeneij F. Transradial access for primary percutaneous coronary intervention: the next standard of care? Heart 2010;96:1341-4.

33. Vuurmans T, Byrne J, Fretz E, et al. Chronic kidney injury in patients after cardiac catheterisation or percutaneous coronary intervention: a com-parison of radial and femoral approaches (from the British Columbia Cardiac and Renal Registries). Heart 2010;96:1538-42.

34. Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet 2011;377:1409-20.

35. Siller-Matula JM, Huber K, Christ G, et al. Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary inter-vention: a systematic review and meta-analysis. Heart 2010;97:98-105.

36. Patti G, Barczi G, Orlic D, et al. Outcome com-parison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percu-taneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myo-cardial Infarction) randomized study. J Am Coll Cardiol 2011;58:1592-9.

37. Breet NJ, van Werkum JW, Bouman HJ, et al. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart 2011;97:983-90.

38. Bouman HJ, Harmsze AM, van Werkum JW, et al. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coro-nary stenting. Heart 2011;97:1239-44.

39. Park KW, Park JJ, Lee SP, et al. Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic sub-study of the CILON-T randomised controlled trial. Heart 2011;97:641-7.

40. Price MJ, Berger PB, Teirstein PS, et al; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after per-cutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097-105.

41. Sambu N, Dent H, Englyst N, et al. Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study. Heart 2011;97:1661-7.

42. Warner TD, Armstrong PC, Curzen NP, et al. Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists? Heart 2010;96:1693-4.

43. Smit JJ, van Werkum JW, ten Berg J, et al. Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy. Heart 2010;96:1815-20.

44. Hill RA, Chung H, George E, et al. Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention: NICE tech-nology appraisal guidance. Heart 2010;96:1407-8.

45. Eshaghian S, Shah PK, Kaul S. Advances in anti-platelet treatment for acute coronary syndromes. Heart 2010;96:656-61.

46. Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.

47. Wallentin L, Becker RC, Budaj A, et al. PLATO

48. Investigators, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.

49. Mahoney EM, Wang K, Arnold SV, et al. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in myocar-dial infarction TRITON-TIMI 38. Circulation 2010; 121:71-9.

50. Nikolic E, Janzon M, Hauch O, et al. Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. Eur Heart J. Published Online First: 19 June 2012.

51. Hochtl T, Farhan S, Wojta J, et al. New anti-coagulant agents in acute coronary syndromes. Heart 2010;97:244-52.

52. Stone GW, Witzenbichler B, Guagliumi G, et al; HORIZONS-AMI Trial Investigators. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011;377:2193-204.

53. Schwenkglenks M, Toward TJ, Plent S, et al. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST- segment elevation myocardial infarc-tion. Heart 2012;98:544-51.

54. Koutouzis M, Lagerqvist B, James S, et al. Un-fractionated heparin administration in patients treated with bivalirudin during primary percuta-neous coronary intervention is associated with lower mortality and target lesion thrombosis:a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Heart 2011; 97:1484-8.

55. Langrish JP, Fox KA. Optimal antithrombotic treat-ment during primary percutaneous coronary intervention? Heart 2011;97:1459-60.

56. Silvain J, Beygui F, Bartheeleemy O, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary interven-tion: systematic review and meta-analysis. BMJ. 2012;344:e553.

57. Parise H, Maehara A, Stone GW, et al. Meta-analysis of randomized studies comparing intra-vascular ultrasound versus angiographic guidance of percutaneous coronary intervention in pre-drug-eluting stent era. Am J Cardiol 2011;107:374-82.

58. Gauss S, Achenbach S, Pflederer T, et al. Assess-ment of coronary artery remodelling by dual-source CT: a head-to-head comparison with intra-vascular ultrasound. Heart 2011;97:991-7.

59. Schepis T, Marwan M, Pflederer T, et al. Quan-tification of non-calcified coronary atherosclerotic plaques with dual-source computed tomography: comparison with intravascular ultrasound. Heart 2010;96:610-15.

60. Tahara S, Bezerra HG, Sirbu V, et al. Angiographic, IVUS and OCT evaluation of the long-term impact of coronary disease severity at the site of over-lapping drug-eluting and bare metal stents: a sub-study of the ODESSA trial. Heart 2010;96:1574-8.

61. Inoue T, Shite J, Yoon J, et al. Optical coherence evaluation of everolimus-eluting stents 8 months after implantation. Heart 2010;97:1379-84.

62. Stone GW, Maehara A, Lansky AJ, et al. A pros-pective natural-history study of coronary atheros-clerosis. N Engl J Med 2011;364:226-35.

63. Li QX, Fu QQ, Shi SW, et al. Relationship between plasma inflammatory markers and plaque fibrous cap thickness determined by intravascular optical coherence tomography. Heart 2010;96:196-201.

64. Her SH, Yoo KD, Park CS, et al. Long-term clinical outcomes of overlapping heterogeneous drug-eluting stents compared with homogeneous drug-eluting stents. Heart 2011;97:1501-6.

65. Behan MW, Holm NR, Curzen NP, et al. Simple or complex stenting for bifurcation coronary lesions: a patient-level pooled-analysis of the Nordic Bifur-cation Study and the British Bifurcation Coronary Study. Circ Cardiovasc Interv 2011;4:57-64.

66. Gwon HC, Hahn JY, Koo BK, et al. Final kissing ballooning and long-term clinical 91. outcomes in coronary bifurcation lesions treated with 1-stent technique: results from the COBIS registry. Heart 2011;98:225-31.

67. Mills NL, Churchhouse AM, Lee KK, et al. Implementation of a sensitive troponin I 92. assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. JAMA 2011;305:1210-16.

68. Jaffe AS, Apple FS, Morrow DA, et al. Being rational about (im)precision: a statement from the Biochemistry Subcommittee of the Joint European Society of Cardiology/American College of Car-diology Foundation/American Heart Association/ 94. World Heart Federation Task Force for the definition of myocardial infarction. Clin Chem 2010;56:941-3.

69. Mills NL, Lee KK, McAllister DA, etal. Implications of lowering threshold of plasma troponin concen-tration in diagnosis of myocardial infarction: cohort study. BMJ 2012;344:e1533.

70. Baker JO, Reinhold J, Redwood S, et al. Troponins: redefining their limits. Heart 96. 2011;97:447-52.

71. Korosoglou G, Lehrke S, Mueller D, et al. Deter-minants of troponin release in patients with stable coronary artery disease: insights from CT angio-graphy characteristics of atherosclerotic plaque. Heart 2010;97:823-31.

72. Goodacre SW, Bradburn M, Cross E, et al. The Randomised Assessment of Treatment using Panel Assay of Cardiac Markers (RATPAC) trial: a ran-domised controlled trial of point-of-care cardiac markers in the emergency department. Heart 2010;97:190-6. 99.

73. Fox KA, Eagle KA, Gore JM, et al. The Global re-gistry of acute coronary events, 1999 to 2009-GRACE. Heart 2010;96:1095-101.

74. Jolly SS, Shenkman H, Brieger D, et al. Quantit-ative troponin and death, cardiogenic shock, cardiac arrest and new heart failure in patients with non-ST- segment elevation acute coronary syndromes (NSTE ACS): insights from the Global Registry of Acute Coronary Events. Heart 2010; 97:197-202. 101.

75. Politi L, Sgura F, Rossi R, et al. A randomised trial of target-vessel versus multi-vessel revascularisa-tion in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up. Heart 2010;96:662-7.

76. Vlaar PJ, Mahmoud KD, Holmes DR Jr, etal. Culprit vessel only versus multivessel 102. and staged percutaneous coronary intervention for multi-vessel disease in patients presenting with ST-segment elevation myocardial infarction: a pair-wise and network meta-analysis. J Am Coll Cardiol 2011;58:692-703.

77. Kornowski R, Mehran R, Dangas G, et al. HORIZONS-AMI Trial Investigators. Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (har-monizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol 2011;58:704-11.

78. Suarez-Barrientos A, Lopez-Romero P, Vivas D, et al. Circadian variations of infarct size in acute myocardial infarction. Heart 2011;97:970-6.

79. Eitel I, Desch S, de Waha S, et al. Long-term prog-nostic value of myocardial salvage assessed by cardiovascular magnetic resonance in acute reper-fused myocardial infarction. Heart 2011;97:2038-45.

80. Mather AN, Fairbairn TA, Ball SG, et al. Reper-fusion haemorrhage as determined 106. by car-diovascular MRI is a predictor of adverse left ventricular remodelling and markers of late arrhythmic risk. Heart 2010;97:453-9.

81. O'Regan DP, Ariff B, Neuwirth C, et al. Assessment of severe reperfusion injury with T2* cardiac MRI in patients with acute myocardial infarction. Heart 2010;96:1885-91.

82. Kharbanda RK. Cardiac conditioning: a review of evolving strategies to reduce ischaemia-reperfusion injury. Heart 2010;96:1179-86.

83. Ludman AJ, Yellon DM, Hasleton J, et al. Effect of erythropoietin as an adjunct to primary per-cutaneous coronary intervention: a randomised controlled clinical trial. Heart 2011;97:1560-5.

84. Pedersen CM, Schmidt MR, Barnes G, et al. Bradykinin does not mediate remote ischaemic preconditioning or ischaemia-reperfusion injury in vivo in man. Heart 2011;97:1857-61.

85. Ikonomidis I, Iliodromitis EK, Tzortzis S, et al. Staccato reperfusion improves myocardial micro-circulatory function and long-term left ventricular

86. remodelling: a randomised contrast echocardio-graphy study. Heart 2010;96:1898-903.

87. Sorensson P, Saleh N, Bouvier F, et al. Effect of postconditioning on infarct size in 112. patients with ST elevation myocardial infarction. Heart 2010;96:1710-15.

88. Patel MR, Smalling RW, Thiele H, et al. Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the 113. CRISP AMI randomized trial. JAMA 2011;306:1329-37.

89. Reed M, Meier P, Tamhane UU, et al. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of ran-domized controlled trials. JACC Cardiovasc Interv 2009;2:645-54.

90. Wi J, Ko YG, Kim JS, et al. Impact of contrast-induced acute kidney injury with transient or persistent renal dysfunction on long-term out-comes of patients with acute myocardial infarc-tion undergoing percutaneous coronary inter-venetion. Heart 2011;97:1753-7.

91. Gallagher S, Knight C. Contrast-induced nephron-pathy in primary percutaneous coronary inter-vention. Heart 2011;97:1723-5.

92. Meier P, Gurm HS. Is simpler also better? Brief sodium bicarbonate infusion to prevent contrast-induced nephropathy. Am J Cardiol 2010;105: 1042-3.

93. Hekimian G, Kim M, Passefort S, et al. Pre-operative use and safety of coronary angiography for acute aortic valve infective endocarditis. Heart 2010;96:696-700.

94. O'Leary DH, Reuwer AQ, Nissen SE, et al. Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial. Heart 2011;97:1143-50.

95. Roffi M. Peripheral arterial disease. Current evi-dence for carotid endarterectomy and carotid artery stenting. Heart 2010;96:636-42.

96. Brott TG, Hobson RW 2nd, Howard G, et al; CREST Investigators. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010;363:11-23.

97. Meier P, Knapp G, Tamhane U, et al. Short term and intermediate term comparison of endar-terectomy versus stenting for carotid artery stenosis: systematic review and meta-analysis of randomised controlled clinical trials. BMJ 2010; 340:c467.

98. Neequaye SK, Halliday AW. Carotid artery sten-ting: the 2011 NICE guidelines. Heart 2011;98: 274-5.

99. Venkatachalam S, Gray BH, Mukherjee D, et al. Contemporary management of concomitant carotid and coronary artery disease. Heart 2010; 97:175-80.

100. Xie W, Liang L, Zhao L, et al. Combination of carotid intima-media thickness and plaque for better predicting risk of ischaemic cardiovascular events. Heart 2011;97:1326-31.

101. Kodali SK, Williams MR, Smith CR, etal. PARTNER Trial Investigators.Two-year outcomes after trans-catheter or surgical aortic-valve replacement. N Engl J Med 2012;366:1686-95.

102. Abdel-Wahab M, Zahn R, Horack M, et al. Aortic regurgitation after transcatheter aortic valve im-plantation: incidence and early outcome. Results from the German transcatheter aortic valve interventions registry. Heart 2010;97:899-906.

103. 100.Rodes-Cabau J, Gutierrez M, Bagur R, et al. In-cidence, predictive factors, and prognostic value of myocardial injury following uncomplicated transcatheter aortic valve implantation. J Am Coll Cardiol 2011;57:1988-99.

104. 101.Reynolds MR, Magnuson EA, Lei Y, et al. Place-ment of Aortic Transcatheter Valves (PARTNER) Investigators. Health-related quality of life after transcatheter aortic valve replacement in in-operable patients with severe aortic stenosis. Circulation 2011;124:1964-72.

105. 102.Gotzmann M, Hehen T, Germing A, et al. Short-term effects of transcatheter aortic valve implant-tation on neurohormonal activation, quality of life and 6-minute walk test in severe and symptomatic aortic stenosis. Heart 2010;96:1102-6.

106. 103.Watt M, Mealing S, Eaton J, et al. Cost-effective-ness of transcatheter aortic valve replacement in patients ineligible for conventional aortic valve replacement. Heart 2011;98:370-6.

107. 104.Reynolds MR, Magnuson EA, Wang K, et al.

108. PARTNER Investigators. Cost- effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: results from the place-ment of aortic transcatheter valves (PARTNER) trial (Cohort B). Circulation 2012;125:1102-9.

109. 105.Piazza N, Otten A, Schultz C, et al. Adherence to patient selection criteria in patients undergoing transcatheter aortic valve implantation with the 18F CoreValve ReValving System. Heart 2010;96: 19-26.

110. 106.Tamburino C, Capodanno D, Ussia GP. TAVI as a threat to surgical practice: "much ado about nothing" or "the quiet before the storm"? Heart 2010;96:1609-10.

111. 107.Grant SW, Devbhandari MP, Grayson AD, et al. What is the impact of providing a transcatheter aortic valve implantation service on conventional aortic valve surgical activity: patient risk factors and outcomes in the first 2 years. Heart 2010; 96:1633-7.

112. 108.Farouque HMO, Clark DJ. Percutaneous mitral valve leaflet repair for mitral regurgitation: NICE guidance. Heart 2010;96:385-7.

113. 109.Feldman T, Kar S, Rinaldi M, et al. Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endo-vascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol 2009;54:686-94.

114. 110.Glower D, Ailawadi G, Argenziano M, et al. EVEREST II Investigators. EVEREST II randomized clinical trial: predictors of mitral valve replace-ment in de novo surgery or after the MitraClip procedure. J Thorac Cardiovasc Surg 2012;143(4 Suppl):S60-3.

115. 111.Gaemperli O, Moccetti M, Surder D, et al. Acute haemodynamic changes after percutaneous mitral valve repair: relation to mid-term outcomes. Heart 2012;98:126-32.

116. 112.Nagueh SF, Groves BM, Schwartz L, et al. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. A multicenter North American registry. J Am Coll Cardiol 2011;58: 2322-8.

117. 113.Ball W, Ivanov J, Rakowski H, et al. Long-term sur-vival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conser-vative versus invasive treatment. J Am Coll Cardiol 2011;58:2313-21.

118. 114.Galve E, Sambola A, Saldana G, et al. Late benefits of dual-chamber pacing in obstructive hypertro-phic cardiomyopathy: a 10-year follow-up study. Heart 2010;96:352-6.

119. 115.Jensen MK, Almaas VM, Jacobsson L, et al. Long-term outcome of percutaneous transluminal septal myocardial ablation in hypertrophic obs-tructive cardiomyopathy: a Scandinavian multi-center study. Circ Cardiovasc Interv 2011;4:256-65.